A. Yu. Antipova

A. Yu. Antipova

Auto-generated profile, based on publicly available information

A. Yu. Antipova

ФБУН НИИ эпидемиологии и микробиологии имени Пастера

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2017 in Russian Journal of Infection and Immunity
Verified
Journal Article
Open access
PDF file
AПArray Ю. Попова
Array Ю. Попова
AБArray А. Бичурина
Array А. Бичурина
ILI. N. Lavrentyeva
I. N. Lavrentyeva
AЖArray В. Железнова
Array В. Железнова
AАArray Ю. Антипова
Array Ю. Антипова
ATAreg Artemovich Totolian
Areg Artemovich Totolian
A goal for measles elimination globally by 2010–2020 was recognized as one of the priorities in the WHO program “Health for All in the 21st Century” (1998). However measles outbreaks occurred in 2010–2016 in countries with high level of measles vaccine coverage including USA and some European countries.Large measles outbreaks were also registered on the African continent and particular in the Republic of Guinea as a result of the decline of measles vaccine coverage due to the Ebola virus epidemic in the Republic of Guinea in 2014–2015. WHO recommends carrying out the routine measles vaccination as well as the supplemental immunization activities after the stop of the Ebola virus transmission. Effectiveness of the activities is definitely connected with the detection of the epidemically significant for the supplemental immunization age groups. The aim of the study was to evaluate the measles immunity level in different age groups of population in the Republic of Guinea. Materials and methods. Twenty five blood serum samples of healthy adult Guineans aged 28–66 and 121 blood serum samples of adolescences and adults admitted to hospital in the town of Kindia (Republic of Guinea) for indoor treatment were tested by ELISA. The specific measles virus antibodies were detected using the following commercial ELISA test-systems produced by Euroimmun Medizinische Labordiagnostika AG Company (Germany): IgM-antibodies — by “Anti-Measles Virus ELISA (IgM)”, IgG-antibodi es — by “Anti-Measles Virus ELISA (IgG)”, IgG-avidity measles virus antibodies — by “Avidity: Anti-Measles Virus ELISA (IgG)”. A part of sera was studied by “Vector-Best IgM-measles” and “Vector-Best IgG-measles” ELISA test-systems (Russia). Results and discussion. The comparative quantitative study of the measles immunity level (i.e. IgG-antibodies titers) of the healthy adult Guineans in 2015 and 2016 revealed the lack of IgGantibodies in serum of only one person aged 30. In 68.7% of cases studied the IgG-antibodies titers didn’t change significantly during the year. In the most part (68.0%) of the 25 tested sera the high levels of the IgG-antibodies titers were detected (≥ 1000 IU/L). In addition the IgG-antibodies of high avidity were revealed in the most part (87.5%) of blood serum samples thus evidencing the history of measles virus infection in the past among the examined adults aged 28+. The ELISA studies of 121 blood serum samples from patients with different clinical diagnosis being on indoor treatment in the hospital of the town of Kindia (Republic of Guinea) revealed 21 anti-measles IgG negative patients. Among patients with the known age (n = 113) IgG-antibodies to measles virus were determined in 78.8% of the samples tested. At the same time in each age group the seronegative patients as well as the patients with low titers of the specific IgG-antibodies to measles virus were revealed. Among patients of 18–40 years of age the part of seronegative patients was equal to 28.5±5.1%. This cohort may be susceptible to measles virus infection and facilitate the support as well as the development of active epidemic process in case of measles outbreaks in the Republic of Guinea.

26 November 2020 in Russian Journal of Infection and Immunity
Verified
Journal Article
Open access
PDF file
VSV. D. Stoiljkovic
V. D. Stoiljkovic
MBM. A. Bichurina
M. A. Bichurina
ILI. N. Lavrentieva
I. N. Lavrentieva
SFS. B. Filipovic-Vignjevic
S. B. Filipovic-Vignjevic
MBM. D. Bancevic
M. D. Bancevic
AAA. Y. Antipova
A. Y. Antipova
In 2017, the WHO registered 23,927 measles cases in 44 out of 53 countries in the European region. In 2018, measles incidence rate increased up to 82,599 cases registered in 48 countries of the region, with a large number of measles-associated deaths. Overall, 72 measles fatalities were registered in 10 European countries, including Serbia (15 cases).Aim of the study: to characterize 2017—2018 epidemiological upsurge of measles incidence rate observed in the Republic of Serbia (RS) and the Northwestern Federal District (NWFD) of the Russian Federation.Materials and methods. During the 2017—2018 season, 944 serum samples were collected from patients with measles, rubella, or exanthematous diseases in the NWFD and tested in the Laboratory of Virology at the St. Petersburg Regional Centre for Measles Surveillance (SPbRC). In 2017—2018, 2,946 serum samples from the Republic of Serbia were analyzed in the SPbRC by using ELISA with IgM measles test system (Vector-Best, Russia; or Siemens, Germany). Urine and swab samples were examined by RT-PCR and used for isolation and genotyping of measles viruses.Results. From 2017 to 2018, 5,798 measles cases were registered in the RS, among which 2,946 were laboratory-confirmed (serological testing and/or PCR). Unvaccinated subjects or those with unknown vaccination status accounted for majority of the cases. Children under 5 years of age and adults aged 30 years and over dominated among measles patients. During this season, 15 deaths were reported. Several genotypes of measles virus circulated in the RS, e.g. В3 Dublin, D8 Gir Somnath, and D8 Herborn. In 2018, 109 measles cases were recorded in the NWFD, 5 of which were imported from abroad. Among patients, adults comprised 64.2%, wherein 74.3% were covered by unvaccinated subjects or those with unknown vaccination status. Rise in measles incidence rate linked to multiple importations of various measles virus genotypes: В3 Kabul; B3 Dublin; D8 Frankfurt; D8 Cambridge; and D8 Gir Somnath.

27 February 2020 in Russian Journal of Infection and Immunity
Verified
Journal Article
Open access
PDF file
ILI. N. Lavrentieva
I. N. Lavrentieva
MBM. A. Bichurina
M. A. Bichurina
AAA. Y. Antipova
A. Y. Antipova
JCJ. Camara
J. Camara
НМН-Ф. - Магассоуба
Н-Ф. - Магассоуба
В2017 г. ВОЗ сообщила о 596 подтвержденных случаях кори в ГР в связи с эпидемической вспышкой 2016 - 2017 гг. Вспышка была купирована после проведения дополнительной иммунизации (ДИ) против кори в двух провинциях страны. Повышение эффективности ДИ связано с выявлением эпидемически значимых групп населения. Цель исследования – анализ случаев кори в 2017-2018 гг. и оценка популяционного иммунитета к вирусу кори в Гвинейской Республике (ГР). Материалы и методы. Всего исследовано 810 образцов сыворотки крови больных с макуло-папулезной сыпью и клиническим диагнозом «корь?» на IgM- и IgG-антитела к вирусу кори. На IgG-антитела к вирусу кори исследовали 445 сывороток крови условно здоровых лиц в возрасте от 7 месяцев до 67 лет. Иммуноглобулины классов M и G выявляли в ИФА с тест-системами Anti-Measles Virus ELISA (IgM) Euroimmun (Германия) и Anti-Measles Virus ELISA(IgG) Euroimmun (Германия). Результаты и обсуждение.В 2017-2018 году эпидемический процесс кори в Гвинейской Республике протекал весьма интенсивно, с существенным преобладанием детей в возрастной структуре заболевших. В2018 г. более половины заболевших (61,6%) – это дети от 1 до 5 лет; вторая по значимости возрастная группа – дети до года (18,6%), что, видимо, связано с нарушениями плановой вакцинации, которой в ГР подлежат дети 9 месяцев. Установлено, что 16,4% заболевших (60 из 366) имели документированные сведения о вакцинации против кори. Возможно, выявление высокой доли заболевших привитых связано с недостаточным иммунным ответом на однократную иммунизацию детей в возрасте 9 месяцев. Возможно также снижение прививочных свойств вакцинных препаратов из-за нарушения «холодовой цепи» в процессе транспортировки вакцин в условиях тропического климата. Общее количество серонегативных к вирусу кори лиц из 445 обследованных составило 8,3%. Однако абсолютное большинство из них – это дети и молодые люди в возрасте от 7 мес до 22 лет, где было выявлено 52,4 % серонегативных лиц. Таким образом, получены результаты, которые свидетельствуют о сохранении интенсивной циркуляции вируса в популяции и необходимости совершенствования эпидемиологического надзора, повышения охвата плановой вакцинацией и проведения кампаний ДИ против кори в ГР.

28 February 2021 in Russian Journal of Infection and Immunity
Verified
Journal Article
Open access
PDF file
MBM. A. Bichurina
M. A. Bichurina
SFS. Filipovic-Vignjevic
S. Filipovic-Vignjevic
ААА. Юрьевна Антипова
А. Юрьевна Антипова
МБМ. Д. Банцевич
М. Д. Банцевич
ILI. N. Lavrentieva
I. N. Lavrentieva
СФС. Б. Филипович-Вигньевич
С. Б. Филипович-Вигньевич
According to the WHO Strategic Plan, measles should be eradicated in 2020 in the five WHO Regions including European Region. However, large measles outbreaks are being periodically registered in diverse European countries. In the Republic of Serbia (SRB), 5,076 measles cases were detected in 2018, among which 15 cases were fatal.Aim of the study was to examine herd immunity to measles and rubella viruses in the population of the Republic of Serbia.Materials and methods. Blood serum samples obtained in 2018 and 2019 from conditionally healthy residents of the Republic of Serbia were tested for the presence of IgG antibodies to measles and rubella viruses in five age groups: I — children from 2 to 6 years old, II — children from 8 to 14 years old, III — 15 to 24 years old, IV — 25 to 49 years old and V — over 50 years old. A total of 1000 samples were obtained, 200 sera in each group. Enzygnost® Anti-Measles virus/IgG and Enzygnost® Anti-Rubella virus/IgG ELISA test systems (Siemens Healthcare Diagnostics Products GmbH, Germany) were used according to the manufacturer's instructions.Results. Overall, around 23.0% and 33.7% of the surveyed persons had no or low level of anti-measles IgG antibody (≥ 275.0 — ≤ 1000.0 IU/1). In age group I, 60% children contained no or “low” anti-measles antibodies titer (29.5% and 30.5%, respectively). In addition, low antibody titer level was mainly detected in individuals from age group II and III (p 0.05). A third of children under 8—14 contained high IgG-antibodies titer against measles ( 3000.0 IU/l) that might serve as an evidence that such subjects recently recovered after measles. Similar results were obtained for IgG antibodies to rubella in the same age groups.Discussion. The study results evidence about altered routine immunization against measles and rubella in children aged 12—15 months (first vaccination) and those at age of 6—7 years (revaccination) with MMR vaccine. The data obtained correlate with official data on coverage with measles and rubella vaccines in the Republic of Serbia.

28 June 2015 in Russian Journal of Infection and Immunity
Verified
Journal Article
Open access
PDF file
AAAnastassia Ya. Antipova
Anastassia Ya. Antipova
ONO. N. Nikishov
O. N. Nikishov
IKI. V. Khamitova
I. V. Khamitova
AСArray В. Семенов
Array В. Семенов
MBM. A. Bichurina
M. A. Bichurina
ILI. N. Lavrentieva
I. N. Lavrentieva
Parvovirus B19 (PV B19) replicates predominantly in progenitor cells of human erythrocytes and is transmitted by an airborne, vertical through and through blood or infected tissues. At-risk are pregnant women, people with immunodeficiency of different nature and individuals who need blood transfusions or organ transplantation. The available data indicate a high risk of infection through transfusion of blood containing the DNA of parvovirus B19, with viral load 105 copies/ml and above (Hourfar M.K. et al., 2011). According to the requirements of national regulations, the production of therapeutic drugs from plasma assumes the use of raw materials, free from viruses or with minimal viral load (Filatova E.C. et al., 2011). In some foreign countries a study of donor blood for the presence of DNA PV B19 is required; in our country the need for such screening is discussed (Giburt E.B. et al., 2013). Due to the fact that parvovirus is resistant to the methods of blood products desinfection, it is especially important to assess the quality of donor blood. Objective: To investigate the prevalence of the two markers parvovirus infection (IgG and PV B19 DNA) in blood samples from one of the blood centers at St. Petersburg. Plasma samples from 100 blood donors from Military Medical Academy blood centre were tested by ELISA for the presence of IgG antibodies of parvovirus B19. Positive samples were tested by PCR for the DNA of parvovirus B19. ELISA test system recomWell Parvovirus B19 IgG (Microgen GmbH, Germany) and diagnostic kits of Federal State Institution of Science «Central research Institute for epidemiology» of Rospotrebnadzor (Moscow, Russia) which are approved for use in RF was used according to the manufacturers instructions. It was shown that 78 out of 100 donors aged 18 to 58 years had IgG-antibodies.76 positive blood plasma samples were investigated by PCR, with the 19 donors have found DNA of parvovirus B19 (25%). Viral load of one donor was 106 copies/ml. In this case, there is the high risk of infection for the recipient. Results obtained are consistent with literature data. Obviously, it is need to investigate donor blood for parvovirus B19 presence. Obvious that quantification of the DNA of parvovirus B19 in blood products is need.

30 December 2018 in Russian Journal of Infection and Immunity
Verified
Journal Article
Open access
PDF file
AAA. Yu. Antipova
A. Yu. Antipova
MBM. A. Bichurina
M. A. Bichurina
ILI. N. Lavrentieva
I. N. Lavrentieva
The Western Pacific Region (WPR) is comprised of 37 countries such as China, Japan, Mongolia, Republic of Korea, The Socialist Republic of Vietnam, Papua-New Guinea, Australia, including Pacific Island Countries and Territories (21 countries of PICTs, approx. 3 million people) etc., with a population of 1.85 billion people. Among them, China is the largest and most populous (1.3 billion people) country of the Region. Large measles outbreaks were documented to occur in the Region. In 2003, the Regional Committee announced officially about the WPR action plan on measles elimination 2005, which, however, failed. Since 2012, WPR countries joined the WHO 2012–2020 Global Measles and Rubella Strategic Plan performing a routine measles vaccination (national immunization schedule) or within Expanded Programme on Immunization (EPI). Basically, a two-dose immunization strategy is followed in the WPR countries. Since 2002, measles supplementary immunization activities (SIAs) in children were conducted in the following countries: Japan, Laos, Vietnam, Philippines, Mongolia, Cambodia, Papua New Guinea, and China. Starting from 2005, measles management was considerably improved, demonstrating by 2012 decreased measles incidence rate down to 5.9 cases per million population. In last years, a decreased measles immunization coverage in decreed population groups was noted in the WPR countries that resulted in 2013–2015 measles epidemic involving almost all regional countries. In particular, in China measles incidence rate was 19.6 cases per million population, whereas in the Vietnam Papua New Guinea and Philippines it progressively increased reaching 182.8, 345.9 and 548.0 cases per million population, respectively. Early children not vaccinated according to schedule, adolescents and young adults dominated among measles patients. It was found that measles outbreaks were due to missed vaccination and increased level of vulnerability to measles. Children under one, adolescents and young adults who did not receive a two-dose measles vaccination were in risk group. Analyzing WPR measles epidemiology demonstrated that refusal of parents to vaccinate children, poor knowledge of advantages related to vaccination, insufficient immunization coverage in immigrants, travelers, subjects changing place of residence, workers of healthcare and educational facilities require special attention. In 2017–2018 season, the following measles genotypes were found in the WPR: D8 — Australia, New Zealand, Republic of Korea, Singapore, Japan; Н1 — China; В3 — Philippines, Australia and Japan; D9 — Singapore, Australia, Macau (China), Malaysia and Japan, Н2 strains endemic in Vietnam. According to the WHO, measles endemic transmission has been successfully interrupted; Australia, Macau, Mongolia and Republic of Korea are being verified to eliminate measles; Hong Kong (China) and Singapore (based on available information) are ready to verify measles elimination. Thus, in the Western Pacific Region measles elimination is achievable after solving current issues such as increasing and maintaining high-level routine vaccination and conducting measles supplementary immunization campaigns in epidemically important contact clusters.